The at-home monitoring device is designed to track early signs of asthma and provides clinicians with continuous or on-demand remote monitoring of lung sounds. The real-time data enables healthcare professionals to monitor a child’s condition between clinic visits and respond early if a child’s symptoms worsen.

The easy-to-wear device, called AeviceMD, was developed by Aevice Health, a Singaporean digital health company and a graduate of the Cedars-Sinai Accelerator program.

“I saw strong potential in this technology to support how we monitor and manage children with reactive airway issues like asthma outside of the clinical setting,” said Irina Dralyuk, MD, a pediatric pulmonologist at Guerin Children’s. “Being able to assess respiratory symptoms in real time, especially overnight, provides valuable information that can guide earlier intervention and help prevent more serious breathing complications.”

About 4.5 million children in the United States have asthma, making it one of the most common chronic pediatric diseases. Traditionally, doctors have monitored children with asthma through periodic clinic visits and caregiver-reported symptoms such as rapid breathing, chest congestion and breathing difficulties.

However, asthma symptoms often fluctuate widely between visits, and self-reported symptoms are often unreliable. This makes managing worsening symptoms between appointments very difficult.

The wearable stethoscope allows parents to utilize the device at home to record lung sounds and securely share recordings with their doctors. The data enables doctors to build a more complete picture of disease progression, track medication use and assess how patients’ symptoms evolve in response to their treatment plan.

“What we’re trying to do is prevent exacerbations, reduce hospitalizations and emergency department visits, and limit the need for interventions such as systemic steroid use to control asthma symptoms,” Dralyuk said. “Intervening early could decrease chronic inflammation and improve lung function and health over time.”

Children can wear the device, about the size of a half-dollar coin, on the chest for up to 10 hours a day. It is designed for use in children 3 and older.

“We built AeviceMD to make this kind of continuous symptom visibility possible. Having our technology deployed at a large, world-class health system like Cedars-Sinai validates our belief that there is a critical, unmet patient need,” said Adrian Ang, CEO of Aevice Health.

The device is the result of a multiyear collaboration with Cedars-Sinai that began in 2022 and included clinical input from physicians at Guerin Children’s. The collaboration included key regulatory milestones and a pilot program to evaluate the device’s effectiveness in pediatric respiratory monitoring. In 2023, the device received clearance from the U.S. Food and Drug Administration.

“This collaboration demonstrates the importance of providing clinical and operational support to help advance a company’s promising technology toward real-world patient benefit,” said Nirdesh K. Gupta, PhD, managing partner of Cedars-Sinai Intellectual Property Company. “It’s an exciting example of how innovation can directly impact care and improve the way we manage chronic conditions like asthma.”

Read more from Cedars-Sinai Stories and Insights: Common Breathing Problems in Kids and How to Treat Them

The investigators want to study how the weakened gravitational pull in space affects the growth of organoids—small collections of cells that emulate the form and function of human organs. Scientists use organoids to model diseases and test drugs, and the hope is that they will grow more quickly in space than on Earth.

Putting Research Into Practice

“Our ultimate goal is to accelerate the progress of biological research and discovery,” said Arun Sharma, PhD, director of the Center for Space Medicine Research and research scientist in the Board of Governors Regenerative Medicine Institute at Cedars-Sinai. “Our partnership with Exobiosphere furthers Cedars-Sinai’s mission to be at the forefront of space biomedicine while deepening our understanding of how organoids develop in microgravity.”

Sharma and his colleagues hope to speed the discovery of therapies that treat medical issues astronauts experience, including bone and muscle loss and heart and immune system degradation. These discoveries could also be applied to terrestrial patients experiencing similar conditions, such as sarcopenia (muscle loss), osteoporosis (bone weakening) and cardiomyopathy (enlargement, stiffening or weakening of the heart muscle).

“Drugs that are used to treat astronauts can also benefit people on Earth, making a potential broader impact for millions of patients,” Sharma said.

Partnering to Solve Challenges of Research in Space

Microgravity offers tremendous opportunities for scientific discovery but also creates challenges that investigators don’t face on Earth. For example, when astronauts open petri dishes in space, the fluid and cells inside drift out.

However, a Cedars-Sinai study co-authored by Sharma and led by Maedeh Mozneb, PhD, from the Sharma Lab, found that in 96-well plates—rows of tiny wells much smaller than petri dishes—surface tension is strong enough to hold the contents in place.

“It was the first time that anybody has ever showed that you can take this piece of affordable hardware that’s commonly used in labs on ground and bring it to space to do cell biology research,” said Sharma, a research professor in the Department of Biomedical Sciences and the Smidt Heart Institute. “In a way, it's democratizing life sciences.”

Building on this discovery, Exobiosphere developed a research platform that automates organoid experimentation in microgravity. The hardware integrates precision liquid handling, environmental control, robotic manipulation and live imaging—capabilities that previously required intensive astronaut intervention.

"This system is designed to remove barriers for scientists," said Kyle Acierno, CEO of Exobiosphere. "By streamlining the complexity of space-based research, we’re enabling our partners to focus on the science itself—delivering data faster, with greater consistency, and at a scale that’s never been possible in orbit."

The unit, about the size of a carry-on suitcase, accommodates six 96-well plates and includes a built-in incubator, microfluidic‑based liquid dispenser, plate reader and robotic arm. While optimized for microgravity, the platform can also enhance lab productivity on Earth.

Exobiosphere’s innovative work earned it a spot in the Cedars-Sinai Accelerator+ program, which invests in startups focused on improving healthcare to help bring their products to market. Cedars-Sinai Technology Ventures also recently made a $1.4 million investment in the company and will provide mentorship from researchers.  

"As an academic medical center committed to innovation, we are thrilled to invest in a company conducting important biosciences research in space while collaborating with our colleagues at the Center for Space Medicine Research," said Nirdesh K. Gupta, PhD, managing partner of Cedars-Sinai Intellectual Property Company. "Our work together exemplifies our dedication to advancing breakthrough technologies that transform healthcare in space and on Earth."

Read more from Discoveries: Space Doctors and Stem Cell Production in Microgravity

Momentum Spine, a graduate of the Cedars-Sinai Accelerator program, is an AI, mobile spine-imaging and monitoring platform. The platform personalizes the monitoring of spinal deformities while reducing the lifelong consequences of repeated radiation exposure.

“This technology is a true game changer, allowing many of our patients outside Southern California to receive radiation-free scoliosis assessments without the need for travel,” said David Skaggs, MD, co-director of Cedars-Sinai Spine, executive vice chair of the Department of Orthopaedics and director of Pediatric Orthopaedics at Cedars-Sinai Guerin Children's. “Scoliosis can progress rapidly in growing children; this tool allows us to monitor changes closely and intervene early when needed.”

The pilot program, launched at Cedars-Sinai Guerin Children’s, centers on Momentum Spine’s AI-driven, 3D-scanning technology, which enables radiation-free scoliosis assessments and digital models of the patient’s spine.

Parents can utilize the Momentum Spine application on their mobile phones to record a 45-second video of their child standing still while the parent walks around their child. This video is then automatically converted into a 3D model and analyzed by AI to determine the Cobb angle—a measurement used by healthcare providers—to determine the degree of spinal curvature in conditions like scoliosis. Both the 3D model and the analysis results are shared with the care team through a secure web portal. 

Patients also get electronic sensors that are fitted into the custom-fitted back braces. Through the advanced sensor technology and AI-driven, 3D analytics, clinicians can optimize treatment strategies while providing personalized feedback to patients and their families.

Traditionally, physicians rely on in-person visits, X-rays and self-reported brace compliance to treat scoliosis patients.

"Momentum Spine empowers parents to partner with their child’s doctor by providing real-time tracking of brace wear and scoliosis progression,” said Elaine Butterworth, RN, pediatric nurse navigator and the director of Patient Experience and Education for the Pediatric Spine Program. “By increasing compliance and reducing the need for frequent in-person visits, this technology enhances both patient care and peace of mind for families."

Patients also benefit from reduced travel—especially for those in rural areas. The app also enables closer monitoring and earlier intervention when necessary.

“Cedars-Sinai is the first health system to integrate Momentum Spine with both 3D scanning and brace sensors into its pediatric clinics,” said Philippe Miller, CEO of Momentum Health. “This collaboration is a significant step forward in spinal health, as we share the same goal—to ensure every child receives the best possible scoliosis care.”

Read more on the Cedars-Sinai Blog: Seeking a Second Opinion for a Spine Condition

During the Demo Day program, leaders from the 10 startup companies selected to participate in the accelerator program will take to the stage in Las Vegas and pitch their products and progress to potential investors, mentors, healthcare executives and members of the media.

Women's and maternal health will be a key focus area for several startups.  Innovative, tech-driven approaches range from reducing maternal mortality rates by utilizing artificial intelligence-powered strategies to developing new solutions for patients with chronic conditions who need accommodations.

The Cedars-Sinai Accelerator offers a mentorship-driven program for early-stage healthcare and health-tech companies. Each participating company receives an investment of $100,000 and the company’s leaders spend three months receiving hands-on mentoring from Cedars-Sinai experts.

Since its inception in 2016, the accelerator has supported more than 90 early-stage health-tech ventures across four continents that have participated in the accelerator program. Cumulatively, alumni companies have raised more than $800 million in funding.

"Over the past three months, these health-tech companies have gained invaluable insights into the complexities of the healthcare industry,” said Nirdesh K. Gupta, PhD, managing partner of Cedars-Sinai Intellectual Property Company. “Our goal is to boost the development of the next generation of healthcare and biomedical enterprises that will transform healthcare quality and care delivery at Cedars-Sinai and beyond.”

Companies Participating in Demo Day 

• Elaborate offers software to automate clinical administrative tasks and deliver patient-friendly lab results. The company focuses on reducing healthcare providers' in-basket time and improving patients' understanding of their health data.
• Fraiya creates AI-powered tools for pregnancy ultrasound that improve medical diagnoses, empower healthcare professionals and enhance patient care.
• HealthPlus.ai’s solution, PERISCOPE, is an AI-based decision-support tool that accurately predicts infection risks using existing electronic health record data. The Netherlands-based company aims to facilitate early medical intervention and reduce unnecessary hospital stays.
• HERA Biotech is a Texas-based company that seeks to harness biotechnology to address unmet needs in women’s health, specifically reproductive medicine. The company’s initial solution is to commercialize MetriDx, a novel, nonsurgical test that provides definitive diagnosis and staging of endometriosis.
• iCardio.ai develops AI-based software to analyze echocardiograms and produce cardiologist reports. It recognizes multiple pathologies and identifies at-risk patients, increases visibility into abnormalities, and increases the accuracy of a diagnosis.
• Kinexcs, a Singapore-based company, offers KIMIA Recover, a postsurgical monitoring device that allows remote monitoring of joint conditions and provides live feedback to patients on a regular basis.
• Momentum Health from Canada is a digital health application that leverages 3D imaging and artificial intelligence to screen for scoliosis and monitor patients remotely.
• Neu Health, a London-based company, provides a smartphone-based platform and patient program designed to monitor and manage symptoms of Parkinson's disease and dementia. The platform uses AI and machine learning to predict clinical outcomes and optimize care.
• NOMA AI, a Pittsburgh-based company, is a clinical decision-support tool that aims to identify maternal hemorrhage risk earlier and more accurately.
• Pulse Charter Connect is a Chicago-based company that provides a digital platform to optimize and automate coordination and logistics processes for organ transport.

To schedule an interview, contact:

• Cara Martinez at cara.martinez@cshs.org or 310-562-7821
• Shishira Sreenivas at shishira.sreenivas@cshs.org or 202-297-0220

As the managing partner at CSIP Co., Gupta will oversee the growth and co-development of healthcare and life sciences innovations and investments. He will focus on creation of new ventures and building early-stage relationships with technology companies and guiding them through the commercialization process.

In his role leading Technology Ventures Seed and Equity Investments, Gupta was pivotal in the creation of several Cedars-Sinai spinoffs and led equity investments in over 20 companies, achieving multiple successful exits. Under his leadership, the enterprise secured more than 1,200 patents covering a wide range of medical technologies at Cedars-Sinai. Additionally, more than 100 licenses were executed, and over 60 technologies were developed, leading to successful co-development and product launches. These efforts collectively generated over $1 billion in income. Commercializing scientific and medical innovation provides crucial support for Cedars-Sinai’s research initiatives and charitable mission. With his demonstrated ability to scale and bring new inventions to market, Gupta will continue to carry out Cedars-Sinai’s mission.

“We congratulate Dr. Gupta on his well-deserved appointment,” said James Laur, JD, chief executive of Intellectual Property and Health Ventures and co-founder of the Cedars-Sinai Accelerator. “Dr. Gupta’s exceptional operational leadership has led our Technology Venture enterprise to become a uniquely successful program consistently ranked nationally among the top 10 programs.”

Since joining Cedars-Sinai in 2012, Gupta has provided leadership to Cedars-Sinai Technology Ventures, the Cedars-Sinai Accelerator, and Business Units and Commercial Enterprises at Cedars-Sinai, such as Coronet Ventures (Singapore), 3rd Street Diagnostics, the Medically Associated Science and Technology (MAST) program, Quantitative Diagnostic Software Group (QUAD) and Cedars-Sinai Biomanufacturing Center. Gupta has played an integral and strategic role in developing an international network of academic, industry, and venture partners with deep relationships in Singapore, the United Kingdom and the Netherlands.

“I am thrilled to take on this new role and contribute to the ambitious plans of the Cedars-Sinai Intellectual Property Company,” Gupta said. “I look forward to collaborating with faculty and institutional leadership to support the growth and optimization of existing programs, expanding our initiatives and driving innovation to new heights as we optimize healthcare and improve the quality of life for patients at Cedars-Sinai.”

Prior to joining Cedars-Sinai, Gupta was the director of research and development at California State University, Los Angeles. He was a nominated member of the Business Advisory Council of the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP) and has served on its Innovation and Competitiveness Task Force.

Gupta holds a PhD in medicinal and biological chemistry and a bachelor’s degree in pharmacy.

Read more on the Cedars-Sinai Blog: Virtual Reality and the Brain-Body Connection

During the three-month program, participating companies will have the opportunity to network and seek mentorship from more than 300 clinicians, executives and resources across Cedars-Sinai.

Participants will receive personalized guidance, support, and exposure to a vast network of healthcare entrepreneurs, investors and advisers to help navigate the companies’ healthcare solutions to the next level.

“We are excited to welcome the teams from the 10 companies in our next cohort of the accelerator. Each group is bringing technology solutions that have the potential to help us deliver healthcare to our patients in a more efficient and cost-effective manner,” said James Laur, JD, chief executive, Intellectual Property and Health Ventures, and co-founder of Cedars-Sinai Accelerator. 

Companies in the accelerator’s 10^th class are working on various innovative technology-driven healthcare solutions, including software that detects heart disease early, a program that mines data to improve or predict health outcomes, and monitoring devices that provide real-time feedback remotely to promote telehealth.

Women’s and maternal health is the focus of several companies in the incoming class, such as artificial intelligence-powered strategies to reduce maternal mortality rates and meaningful solutions for chronic conditions like endometriosis.

Each participating company will receive an investment of $100,000 to bolster its product growth and vision.

At the end of the three-month program, as part of Cedars-Sinai’s Demo Day, entrepreneurs will present their products and share their progress at the HLTH Event 2024 conference in Las Vegas to an audience of potential investors, startups, government and healthcare policymakers, health-tech consumers and journalists.

"Building a successful company in the healthcare industry requires more than just a great idea; it demands an understanding of the complexities of healthcare,” said Nirdesh K. Gupta, PhD, managing partner of Cedars-Sinai Intellectual Property Company. “Each accelerator class brings new opportunities for the Cedars-Sinai community to make a difference. We are excited to continue our mission of transforming healthcare and research in Los Angeles and beyond.”

The10th Cedars-Sinai Accelerator class includes:

• Elaborate offers software to automate clinical administrative tasks and deliver patient-friendly lab results. The company aims to reduce healthcare providers' in-basket time and improve patients' understanding of their health data.
• Fraiya creates AI-powered tools for pregnancy ultrasound that improve medical diagnoses, empower healthcare professionals and enhance patient care.
• HealthPlus.ai’s solution, PERISCOPE, is an AI-based decision-support tool that accurately predicts infection risks using existing electronic health record data. The Netherlands-based company aims to facilitate early medical intervention and reduce unnecessary hospital stays.
• HERA Biotech is a Texas-based company that aims to harness biotechnology to address unmet needs in women’s health, specifically reproductive medicine. The company’s initial solution is to commercialize MetriDx, a novel, nonsurgical test that provides definitive diagnosis and staging of endometriosis.
• iCardio.ai develops AI-based software to analyze echocardiograms and produce cardiologist reports. It recognizes multiple pathologies and identifies at-risk patients, increases visibility into abnormalities, and increases the accuracy of a diagnosis.
• Kinexcs, a Singapore-based company, offers KIMIA Recover, a postsurgical monitoring device that allows remote monitoring of joint conditions and provides live feedback to patients on a regular basis.
• Momentum Health from Canada is a digital health application that leverages 3D imaging and artificial intelligence to screen for scoliosis and monitor its progression remotely.
• Neu Health, a London-based company, provides a smartphone-based platform and patient program designed to monitor and manage symptoms of Parkinson's disease and dementia. It uses AI and machine learning to predict clinical outcomes and optimize care.
• NOMA AI, a Pittsburgh-based company, is a clinical decision-support platform that aims to identify maternal hemorrhage risk earlier and more accurately.
• Pulse Charter Connect is a Chicago-based company that provides a digital platform to optimize and automate coordination and logistics processes for organ transport.

Read more on the Cedars-Sinai Blog: Cedars-Sinai Introduces Dutch Health-Tech Startups to US Markets

“Participants will explore crucial topics such as regulatory requirements, intellectual property best practices, the role of internal review boards, and legal considerations for international companies,” said James D. Laur, JD, chief intellectual property officer at Cedars-Sinai. “Our goal is for these companies to end the week with an awareness of the complex environment that healthcare solutions need to navigate in order to enter the U.S. market.”

Participating companies will have the opportunity to learn from members of Cedars-Sinai Technology Ventures group, which brings medical innovations to the global marketplace by directing the commercial development of research through long-term relationships with industry partners and investors. The team’s goal is to advance healthcare solutions and improve the health and wellbeing of patients.

As a complement to the work of Technology Ventures, the Cedars-Sinai Accelerator supports the growth and development of early-stage companies focused on improving healthcare and healthcare delivery. Mentors from this program will also interact with these Singapore-based companies to provide guidance and support to help them understand what it takes to develop and scale innovative companies in the U.S. market.

Also offering guidance throughout the innovation week event is co-host Coronet Ventures, Cedars-Sinai Intellectual Property Company’s Singapore-based investment vehicle, which focuses on advancing the development of early-stage health and biomedical startups in Singapore.

“The event is often a pivotal point in a company’s trajectory, and we are eager to see what will be unearthed during our latest innovation week,” said Nirdesh K. Gupta, PhD, managing director of Cedars-Sinai’s Technology Ventures and the accelerator, and CEO of Coronet Ventures.

Gupta said Coronet Ventures aims to invest in 12 to 15 startups over the next five years, with financial support ranging from $500,000 to $5 million.

Enterprise Singapore, a government agency dedicated to supporting the growth of Singapore enterprises, will also participate in the Cedars-Sinai event, as it has been a longtime supporter of Coronet Ventures.

“The U.S. has the largest healthcare market in the world and offers vast opportunities for emerging biomedical startups,” said Clarice Chen, PhD, director of Healthcare and Biomedical at Enterprise Singapore. “The nation also has a mature ecosystem that offers access to leading healthcare companies, FDA [Food and Drug Administration] approval, clinical trials, and venture capital. We are pleased to collaborate with Cedars-Sinai to assist Singapore startups in navigating the healthcare landscape and establishing their footprint in the U.S.”

The 11 participating companies are: 

• BluMaiden Biosciences is an artificial intelligence-guided (AI-guided) drug discovery company providing actionable clinical insights to enhance clinical trial decision-making through its Pharma Service, and identifying licensable small molecule drugs via its flagship platform MAIDENTM.
   
• Carecam is redefining therapeutics by creating digital biomarkers from human body motion to enable early interventions and deliver personalized care for neurodegenerative and cardiovascular diseases.
   
• HiCura develops AI ultrasound guidance software for interventional radiology procedures.
   
• Kinexcs is an AI-driven digital health platform and wearables company with a mission to enable and empower people for mobility and a better quality of life.
   
• Kronikare is revolutionizing chronic wound care with early detection and efficiency. The AI-powered KroniKare Wound Scanner sets a new standard in healthcare technology.
   
• KYAN Technologies has a novel technology platform that combines small data AI and biological experiments in order to support clinicians to truly personalize treatment for their cancer patients and also work with pharmaceutical companies to efficiently discover drug-dose combinations.
   
• NalaGenetics develops next-generation genomic interpretation for germline sequencing, focusing on diverse populations. The company combines monogenic risk, polygenic risk, and clinical/epigenetic risk, and suggests personalized prevention strategies for cancer, cardiometabolic disorders, psychiatry, and neurodegenerative conditions.
   
• NousQ is developing the world's first robotic, handheld, automated device that inserts ear tympanostomy tubes with just one click, thus facilitating in-clinic/local anesthesia surgery instead of the usual operating theater and general anesthesia surgery. This increases affordability, adoption and access.
   
• Pedra Technology’s perfusion monitor is a Food and Drug Administration-designated breakthrough device that provides precision guidance during endovascular procedures to treat critical limb-threatening ischemia, with early U.K. data showing the potential for reducing readmission and amputation rates.
   
• Qritive designs and deploys AI-powered solutions that enable histopathologic diagnosis of cancer at scale, resulting in improved patient outcome and better health equity.
   
• TIIM Healthcare is revolutionizing cardiac triage through AI-powered software, enabling doctors to assess chest pain patients with speed, enhanced accuracy and confidence.

Read more on the Cedars-Sinai Blog: How AI Is Born: Patient Needs Drive Development

During the three-month program, company leaders get hands-on experience, along with mentorship from Cedars-Sinai researchers, administrators and clinicians, to develop and refine the practical applications of their products and solutions.

"I’m excited to welcome these innovative teams from around the globe who are developing new technologies which have the promise to enhance the delivery of efficient and cost-effective patient care," said James Laur, JD, vice president of Intellectual Property, managing director of Cedars-Sinai Technology Ventures and one of the accelerator’s founders.  

In addition to the personalized guidance, each company will receive a $100,000 investment from Cedars-Sinai. After completing the three-month program, company leaders will share their progress with an audience of investors, mentors, potential customers and members of the news media at a Demo Day.

"The provision of strategic and operational insights at the outset of development plays a pivotal role in driving healthcare innovations, and each accelerator class brings that opportunity to the Cedars-Sinai community," said Nirdesh K. Gupta, PhD, managing director of Cedars-Sinai Technology Ventures. "With our next class, we are looking forward to continuing to transform healthcare and research here in Los Angeles and beyond."

The ninth Cedars-Sinai Accelerator class includes:

52North—Cambridge, U.K.-based company 52North Health develops a medical device that can be used by patients outside of the hospital to monitor their risk of neutropenic sepsis, a life-threatening complication of chemotherapy. The device, Neutrocheck, offers at-home testing using blood from a small pinprick.

Acorai—Stockholm, Sweden-based company Acorai develops a device for heart failure management through noninvasive intracardiac pressure monitoring to help reduce hospitalizations and readmissions. The Acorai Heart Monitor combines seismic, audio, visual and electrical sensors, and captures and analyzes data in real time using machine learning.

Alva Health—New Haven, Connecticut-based Alva Health develops wearable monitoring devices designed for early stroke detection. The system uses machine learning to monitor the onset of hemiparesis (paralysis on one side of the body). When the system detects stroke, the device notifies the user immediately. If there is no response from the user, the device can connect users with emergency responders.

CARI Health—San Diego, California-based CARI Health develops a remote medication monitor to enable personalized dosing and real-time medication adherence monitoring. CARI’s solution combines proprietary core sensing technology with just-in-time intervention software, mobile apps, data and AI to detect medication levels in real time.

equalityMD—Richmond, Virginia-based equalityMD develops a community-centric platform for LGBTQ+ patients to share and connect with others. The platform also provides telehealth services by connecting to clinicians, enabling LGBTQ+ patients to share their experiences and foster a true sense of community around health and wellness.

Machine Medicine—London, U.K.-based Machine Medicine develops a platform that helps researchers capture and assess motor functioning in patients with neuromodulation devices. KELVIN (the software component) enables anyone to do a motor assessment remotely via their smartphone, allowing for faster and more frequent patient monitoring.

Paperplane Therapeutics—Quebec, Canada-based Paperplane Therapeutics designs therapeutic virtual reality video games aimed at improving pain and anxiety management in children undergoing various medical treatments or procedures.

Predicta Med—Ramat Gan, Israel-based Predicta Med develops a solution for early detection and treatment selection for undiagnosed autoimmune diseases. Predicta Med’s deep learning engine aggregates electronic medical record and claims data, and enriches and analyzes this data to identify patients at risk of having an autoimmune disease and provide actionable insights to enable optimal intervention.

RCE.ai—Carlsbad, California-based RCE Technologies develops a noninvasive device that monitors cardiac proteins in the blood, empowering emergency medicine physicians and cardiologists in the early assessment of patients presenting with chest pain.

TestDynamics—Austin, Texas-based TestDynamics develops a platform that offers hospitals and physicians one-stop, intelligent access to a wide range of AI models for medical imaging. It aims to improve patient care outcomes, reduce healthcare costs and lower malpractice risk.

Read more in Discoveries: From Idea to Innovation